SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$38.04 USD
+1.17 (3.17%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $38.00 -0.04 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
SpringWorks Therapeutics (SWTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$65.50 | $75.00 | $52.00 | 77.65% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for SpringWorks Therapeutics comes to $65.50. The forecasts range from a low of $52.00 to a high of $75.00. The average price target represents an increase of 77.65% from the last closing price of $36.87.
Analyst Price Targets (8 )
Broker Rating
SpringWorks Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, eight are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SWTX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/2/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
3/6/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
2/26/2024 | Goldman Sachs | Corinne Johnson | Strong Buy | Strong Buy |
2/5/2024 | Guggenheim Securities | Michael Schmidt | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 8 |
Average Target Price | $65.50 |
LT Growth Rate | 21.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -1.12 |